NASDAQ:APLT Applied Therapeutics (APLT) Stock Price, News & Analysis $0.34 0.00 (-0.38%) Closing price 07/3/2025 03:50 PM EasternExtended Trading$0.34 0.00 (-0.30%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Applied Therapeutics Stock (NASDAQ:APLT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Applied Therapeutics alerts:Sign Up Key Stats Today's Range$0.32▼$0.3550-Day Range$0.30▼$0.6052-Week Range$0.30▼$10.62Volume1.86 million shsAverage Volume3.43 million shsMarket Capitalization$47.71 millionP/E RatioN/ADividend YieldN/APrice Target$6.10Consensus RatingModerate Buy Company Overview Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York. Read More Applied Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks76th Percentile Overall ScoreAPLT MarketRank™: Applied Therapeutics scored higher than 76% of companies evaluated by MarketBeat, and ranked 237th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingApplied Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageApplied Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Applied Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Applied Therapeutics are expected to grow in the coming year, from ($0.65) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Applied Therapeutics is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Applied Therapeutics is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioApplied Therapeutics has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Applied Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.31% of the float of Applied Therapeutics has been sold short.Short Interest Ratio / Days to CoverApplied Therapeutics has a short interest ratio ("days to cover") of 9.9.Change versus previous monthShort interest in Applied Therapeutics has recently increased by 18.43%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldApplied Therapeutics does not currently pay a dividend.Dividend GrowthApplied Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.88 Percentage of Shares Shorted15.31% of the float of Applied Therapeutics has been sold short.Short Interest Ratio / Days to CoverApplied Therapeutics has a short interest ratio ("days to cover") of 9.9.Change versus previous monthShort interest in Applied Therapeutics has recently increased by 18.43%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 2 people have searched for APLT on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows5 people have added Applied Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Applied Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.60% of the stock of Applied Therapeutics is held by insiders.Percentage Held by Institutions98.31% of the stock of Applied Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Applied Therapeutics' insider trading history. Receive APLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Applied Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address APLT Stock News HeadlinesApplied Therapeutics, Inc. (APLT) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comApplied Therapeutics Announces Key Leadership AppointmentsJune 17, 2025 | globenewswire.comBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly positioned to fill it…July 5 at 2:00 AM | Crypto 101 Media (Ad)Applied announces INSPIRE Phase 2/3 trial primary endpoint not significantMay 18, 2025 | msn.comApplied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual MeetingMay 18, 2025 | globenewswire.comApplied Therapeutics Reports First Quarter 2025 Financial ResultsMay 13, 2025 | globenewswire.comApplied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the Peripheral Nerve Society 2025 Annual MeetingMay 9, 2025 | globenewswire.comNET Power Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. June 17, 2025 Deadline to file Lead Plaintiff MotionApril 22, 2025 | globenewswire.comSee More Headlines APLT Stock Analysis - Frequently Asked Questions How have APLT shares performed this year? Applied Therapeutics' stock was trading at $0.8562 at the start of the year. Since then, APLT shares have decreased by 60.6% and is now trading at $0.3370. How were Applied Therapeutics' earnings last quarter? Applied Therapeutics Inc. (NASDAQ:APLT) announced its quarterly earnings results on Monday, April, 14th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.06. The company earned $0 million during the quarter, compared to analyst estimates of $0.61 million. When did Applied Therapeutics IPO? Applied Therapeutics (APLT) raised $60 million in an initial public offering (IPO) on the week of May 13th 2019. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank served as the underwriters for the IPO and Baird was co-manager. How do I buy shares of Applied Therapeutics? Shares of APLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Applied Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Applied Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), Advanced Micro Devices (AMD) and ServiceNow (NOW). Company Calendar Last Earnings4/14/2025Today7/05/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:APLT CIK1697532 Webwww.appliedtherapeutics.com Phone(212) 220-9226FaxN/AEmployees30Year Founded2017Price Target and Rating Average Stock Price Target$6.10 High Stock Price Target$14.00 Low Stock Price Target$1.50 Potential Upside/Downside+1,710.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$105.62 million Net MarginsN/A Pretax Margin-16,357.52% Return on Equity-184.67% Return on Assets-84.02% Debt Debt-to-Equity RatioN/A Current Ratio3.00 Quick Ratio3.00 Sales & Book Value Annual Sales$460 thousand Price / Sales103.72 Cash FlowN/A Price / Cash FlowN/A Book Value$0.49 per share Price / Book0.69Miscellaneous Outstanding Shares141,580,000Free Float139,311,000Market Cap$47.71 million OptionableOptionable Beta1.82 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:APLT) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Applied Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Applied Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.